Evoke Pharma Inc: Nasdaq/NYSE listing notice — Evoke Pharma receives Nasdaq bid-price deficiency notice; 180-day cure until Aug 19, 2024

Evoke Pharma Inc

On Feb 21, 2024, Nasdaq notified Evoke Pharma its stock bid price closed below $1.00 for 30 consecutive business days, violating Listing Rule 5550(a)(2).
Company has until August 19, 2024 to regain compliance by closing at $1.00 or more for 10 consecutive business days.
No immediate effect on listing; stock continues to trade on Nasdaq under symbol 'EVOK'.
If not cured, company may qualify for an additional 180-day period if it meets other listing standards and considers a reverse stock split.
Failure to cure could lead to delisting; company intends to monitor and explore available options.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Evoke Pharma Inc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

February 21, 2024, Evoke Pharma, Inc. (the “Company”) received a letter from the Nasdaq Stock Market staff indicating that, for the last thirty consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until August 19, 2024, to regain compliance. The letter states that the Nasdaq staff will provide written notif

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0000950170-24-019381

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.